Australia: Infrastructure and Innovations for Clinical Trials
Sponsors seeking venues for pharmaceutical research and development would do well to consider Australia – offering a highly favorable, stable environment and experienced, capable local expertise. This article is the second in a three-part series: Here, we examine the landscape for clinical trials, including infrastructure, government funding support and incentives, patient centricity, patient recruitment, and the adoption of innovation.
Interested in more? Check out part 1 and part 3.
Related Insights
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Blog
Decentralized Trials: Considerations for Building a New Patient-Centric Model
May 13, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?
Feb 1, 2023
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Article
Decentralized clinical trials - A more patient-centric approach
May 10, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Including patients in DCT design
Sep 13, 2022
Video
The 2024 FDA Diversity Guidance Update: What does it mean for patients, sites, sponsors and CROs
Aug 22, 2024
Related Insights
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Blog
Decentralized Trials: Considerations for Building a New Patient-Centric Model
May 13, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Video
The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?
Feb 1, 2023
Report
New Medicines, Novel Insights: Achieving patient-guided drug development
Oct 30, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Article
Decentralized clinical trials - A more patient-centric approach
May 10, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Blog
Including patients in DCT design
Sep 13, 2022
Video
The 2024 FDA Diversity Guidance Update: What does it mean for patients, sites, sponsors and CROs
Aug 22, 2024